• CD47 targeting
  • CD28 targeting
  • How it works

CD47 targeting

Safe and selective blockade of CD47 on tumors

Cancer cells CD47 conveys a «don’t eat me signal» to better escape the immune system. A large body of evidence indicates that blocking the activity of CD47 with monoclonal antibodies restores killing of tumor cells.

One major difficulty is that CD47 is expressed on every cell of the human body.

To overcome this limitation, we have developed a unique bispecific antibody approach to selectively block CD47 on cancer cells, leaving normal cells unaffected.

Do you want to know more about selective CD47 targeting?
Interested by this approach for your own projects? Partner with us.

New publication in Cancer Immunology Research

NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control

Read more

LinkedIn